Cade will evaluate the operation between biopharmaceuticals AstraZeneca and Alexion


Administrative Council for Economic Defense published the concentration act's announcement involving the biopharmaceuticals AstraZeneca PLC and Alexion Pharmaceuticals in the Official Gazette on the 10th of March.

AstraZeneca is a global biopharmaceutical company based in the United Kingdom and the headquarters of the AstraZeneca Group. The company focuses on the discovery, development and commercialization of prescription drugs for the treatment of diseases in the areas of therapy, such as oncology, cardiovascular, renal and metabolic diseases; and respiratory and immunological.

Alexion is a global biopharmaceutical company based in the United States and has a portfolio of therapies and drugs under development focused on rare and ultra-rare diseases.

According to the companies' notification form, the operation represents an opportunity for AstraZeneca to expand patient access to rare disease treatments, taking advantage of Alexion's scientific experience in AstraZeneca therapy's main areas, in addition to its global presence.

According to the law, the competitive analysis of mergers must be completed within 240 days. This legal term can be extended by another 90 days, upon a reasoned decision by CADE's Administrative Court, or by 60 days at the parties' lawyers' request.

CADE can classify concentration acts as summaries, considered simpler from a competitive point of view, or ordinary, which require a more in-depth analysis. The assessment of operations submitted to the summary procedure must be completed within 30 days, as provided in Resolution 02/2012.